{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:07:29Z","timestamp":1766088449515,"version":"3.41.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In chemotherapeutic treatments, while cancer cells are the primary target, cytotoxic side effects are an important consideration. In the current study, we applied an in vivo imaging tool for characterizing chemotherapeutic response in a preclinical setting. The study focused on simultaneously examining the tumor and tissue response as a result of treatment with bortezomib, a mainstay proteasome inhibitor for treating multiple myeloma, in a preclinical model. OPM-2 tumor-bearing SCID-beige mice were designated as control or treated with bortezomib (1\u00a0mg\/kg, i.v., every 4\u00a0days) (n\u2009=\u20098 per group). <jats:sup>99m<\/jats:sup>Tc-duramycin SPECT\/CT whole-body scans were acquired 2\u00a0days before treatment as baseline and at days 1, 3 and 5 after treatment. Radioactivity uptake in tissues and organs was determined and quantitatively compared between control and bortezomib-treated group at each of the time points. Based on the imaging data, separate groups of tumor-bearing mice (n\u2009=\u20093 each) were included as control and bortezomib treated and the tissues were collected on day 5 for histopathology. In vivo imaging data identified significantly elevated <jats:sup>99m<\/jats:sup>Tc-duramycin uptake in the tumor, particularly in tumoral periphery. This was accompanied with signal changes in multiple organs and tissues including the adipose tissue, major bones, abdominal regions, spleen and testes. The imaging findings were consistent with known cytotoxic side effects of bortezomib and were supported by histopathology. The outcome of the study demonstrated potential utilities of the technology by enabling timely determination of the efficacy of anticancer treatments and the effect on collateral tissues as a result of systemic cytotoxic treatment.<\/jats:p>","DOI":"10.1007\/s10495-025-02118-9","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T23:48:13Z","timestamp":1745624893000},"page":"1515-1524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An in vivo imaging approach for simultaneously assessing tumor response and cytotoxicity-induced tissue response in chemotherapy"],"prefix":"10.1007","volume":"30","author":[{"given":"Steven E.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad R.","family":"Haney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha N.","family":"Spann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigar","family":"Khurram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farres","family":"Obeidin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungwha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"2118_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.lungcan.2004.11.018","volume":"48","author":"LJ Fallowfield","year":"2005","unstructured":"Fallowfield LJ, Harper P (2005) Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 48:365\u2013377","journal-title":"Lung Cancer"},{"key":"2118_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-08-3836","volume":"69","author":"WN Hait","year":"2001","unstructured":"Hait WN, Hambley TW (2001) Targeted cancer therapeutics. Cancer Res 69:1263\u20131267","journal-title":"Cancer Res"},{"key":"2118_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1023\/A:1014747300739","volume":"6","author":"GW Sledge Jr","year":"2001","unstructured":"Sledge GW Jr (2001) Breast cancer in the clinic: treatments past, treatments future. J Mammary Gland Biol Neoplasia 6:487\u2013495","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"2118_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2165\/00002018-200023040-00001","volume":"23","author":"FG Jansman","year":"2000","unstructured":"Jansman FG, Sleijfer DT, Coenen JL, De Graaf JC, Brouwers JR (2000) Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 23:255\u2013278","journal-title":"Drug Saf"},{"key":"2118_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/PL00001982","volume":"25","author":"D Iarussi","year":"2000","unstructured":"Iarussi D, Indolfi P, Galderisi M, Bossone E (2000) Cardiac toxicity after anthracycline thermotherapy in childhood. Herz 25:676\u2013688","journal-title":"Herz"},{"key":"2118_CR6","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1200\/JCO.2014.55.9047","volume":"32","author":"CM Walko","year":"2014","unstructured":"Walko CM, McLeod HL (2014) Personalizing medicine in geriatric oncology. J Clin Oncol 32:2581\u20132586","journal-title":"J Clin Oncol"},{"key":"2118_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11864-014-0303-7","volume":"15","author":"DR Pachman","year":"2014","unstructured":"Pachman DR, Watson JC, Loprinzi CL (2014) Therapeutic strategies for cancer treatment related peripheral neuropathies. Curr Treat Options Oncol 15:567\u2013580","journal-title":"Curr Treat Options Oncol"},{"key":"2118_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS (2016) Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 13:659\u2013673","journal-title":"Nat Rev Clin Oncol"},{"key":"2118_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1078\/0171-9335-00171","volume":"80","author":"A Mailloux","year":"2001","unstructured":"Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, Baudin B (2001) Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol 80:442\u2013449","journal-title":"Eur J Cell Biol"},{"key":"2118_CR10","first-page":"734","volume":"59","author":"MM Keane","year":"1999","unstructured":"Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59:734\u2013741","journal-title":"Cancer Res"},{"key":"2118_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jat.2550070402","volume":"7","author":"DJ Pritchard","year":"1987","unstructured":"Pritchard DJ, Wright MG, Sulsh S, Butler WH (1987) The assessment of chemically induced liver injury in rats. J Appl Toxicol 7:229\u2013236","journal-title":"J Appl Toxicol"},{"issue":"5","key":"2118_CR12","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/ijms18051018","volume":"18","author":"A Iorga","year":"2017","unstructured":"Iorga A, Dara L, Kaplowitz N (2017) Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. Int J Mol Sci 18(5):1018","journal-title":"Int J Mol Sci"},{"key":"2118_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0006-8993(03)03450-4","volume":"990","author":"H Kimura","year":"2003","unstructured":"Kimura H, Gules I, Meguro T, Zhang JH (2003) Cytotoxicity of cytokines in cerebral microvascular endothelial cells. Brain res 990:148\u2013156","journal-title":"Brain res"},{"key":"2118_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1124\/mol.105.014712","volume":"68","author":"HY Ryu","year":"2005","unstructured":"Ryu HY, Emberley JK, Schleziger JJ, Allan LL, Na S, Sherr DH (2005) Environmental chemical-induced bone marrow B cell apoptosis: death receptor-independent activation of a caspase-3 to caspase-8 pathway. Mol Pharmacol 68:1087\u20131096","journal-title":"Mol Pharmacol"},{"key":"2118_CR15","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-18-1846","volume":"25","author":"SE Johnson","year":"2019","unstructured":"Johnson SE, Ugolkov A, Haney CR et al (2019) Whole-body imaging of cell death provides a systemic, minimally invasive, dynamic, and near-real time indicator for chemotherapeutic drug toxicity. Clin Cancer Res 25:1331\u20131342","journal-title":"Clin Cancer Res"},{"key":"2118_CR16","first-page":"H242","volume":"274","author":"N Mauilk","year":"1998","unstructured":"Mauilk N, Kagan VE, Tyurin VA, Das DK (1998) Redistribution of phosphatidylethanolamine and phosphatidylserine precedes reperfusion-induced apoptosis. Am J Physiol 274:H242-248","journal-title":"Am J Physiol"},{"key":"2118_CR17","first-page":"3","volume":"146","author":"G Majno","year":"1995","unstructured":"Majno G, Joris I (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146:3\u201315","journal-title":"Am J Pathol"},{"key":"2118_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cbin.11137","volume":"43","author":"MS D'Arcy","year":"2019","unstructured":"D\u2019Arcy MS (2019) Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int 43:582\u2013592","journal-title":"Cell Biol Int"},{"key":"2118_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495\u2013516","journal-title":"Toxicol Pathol"},{"key":"2118_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2967\/jnumed.107.048603","volume":"49","author":"M Zhao","year":"2008","unstructured":"Zhao M, Li Z, Bugenhagen S (2008) 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med 49:1345\u20131352","journal-title":"J Nucl Med"},{"key":"2118_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.nucmedbio.2012.02.004","volume":"39","author":"S Audi","year":"2012","unstructured":"Audi S, Li Z, Capacete J, Liu Y, Fang W, Shu LG, Zhao M (2012) Understanding the in vivo uptake kinetics of a phosphatidylethanolamine-binding agent (99m)Tc-Duramycin. Nucl Med Biol 39:821\u2013825","journal-title":"Nucl Med Biol"},{"key":"2118_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG (2017) The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev 36:561\u2013584","journal-title":"Cancer Metastasis Rev"},{"key":"2118_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","volume":"60","author":"LD Fricker","year":"2020","unstructured":"Fricker LD (2020) Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol 60:457\u2013476","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2118_CR24","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3390\/cancers12092540","volume":"12","author":"E Pancheri","year":"2020","unstructured":"Pancheri E, Guglielmi V, Wilczynski GM et al (2020) Non-hematologic toxicity of Bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects. Cancers (Basel) 12:2540","journal-title":"Cancers (Basel)"},{"key":"2118_CR25","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/ndt\/gfad016","volume":"38","author":"SM Song","year":"2023","unstructured":"Song SM, Jeon J, Jang HR et al (2023) Acute kidney injury in bortezomib-treated patients with multiple myeloma. Nephrol Dial Transplant 38:2077\u20132085","journal-title":"Nephrol Dial Transplant"},{"key":"2118_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","volume":"2","author":"A Field-Smith","year":"2006","unstructured":"Field-Smith A, Morgan GJ, Davies FE (2006) Bortezomib (Velcade\u2122) in the treatment of multiple myeloma. Ther Clin Risk Manag 2:271\u2013279","journal-title":"Ther Clin Risk Manag"},{"key":"2118_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SPC.0000000000000266","volume":"11","author":"RL Stansborough","year":"2017","unstructured":"Stansborough RL, Gibson RJ (2017) Proteasome inhibitor-induced gastrointestinal toxicity. Curr Opin Support Palliat Care 11:133\u2013137","journal-title":"Curr Opin Support Palliat Care"},{"key":"2118_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2967\/jnumed.112.112490","volume":"54","author":"SE Johnson","year":"2013","unstructured":"Johnson SE, Li Z, Liu Y, Moulder JE, Zhao M (2013) Whole-body imaging of high-dose ionizing irradiation-induced tissue injuries using 99mTc-duramycin. J Nucl Med 54:1397\u20131403","journal-title":"J Nucl Med"},{"key":"2118_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2967\/jnumed.115.168344","volume":"57","author":"F Elvas","year":"2016","unstructured":"Elvas F, Vangestel C, Pak K et al (2016) Early prediction of tumor response to treatment: preclinical validation of 99mTc-duramycin. J Nucl Med 57:805\u2013811","journal-title":"J Nucl Med"},{"key":"2118_CR30","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/ijms22020888","volume":"22","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Egashira N (2021) Pathological mechanisms of bortezomib-induced peripheral neuropathy. Int J Mol Sci 22:888\u20131003","journal-title":"Int J Mol Sci"},{"key":"2118_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.taap.2015.04.001","volume":"285","author":"W Li","year":"2015","unstructured":"Li W, Fu J, Zhang S, Zhao J, Xie N, Cai G (2015) The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis. Toxicol Appl Pharmacol 285:98\u2013109","journal-title":"Toxicol Appl Pharmacol"},{"key":"2118_CR32","doi-asserted-by":"publisher","first-page":"68460","DOI":"10.18632\/oncotarget.19536","volume":"8","author":"JP Gro\u00df","year":"2017","unstructured":"Gro\u00df JP, Nattenm\u00fcller J, Hemmer S et al (2017) Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma\u2014subgroup analysis of the prospective GMMG MM5 trial. Oncotarget 8:68460\u201368471","journal-title":"Oncotarget"},{"key":"2118_CR33","first-page":"1987","volume":"21","author":"A Badran","year":"2021","unstructured":"Badran A, Iwasaki H, Wano Y, Kishi S, Ueda T (2021) Time sequential expression of markers of apoptosis induced by 1-beta-D-arabinofuranosylcytosine in human T-lymphoblastic leukemia CCRF-CEM cells. Anticancer Res 21:1987\u20131995","journal-title":"Anticancer Res"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02118-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T05:31:06Z","timestamp":1749879066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":33,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02118-9","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"type":"print","value":"1360-8185"},{"type":"electronic","value":"1573-675X"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"10 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SEJ and MZ are cofounders of Durametrix LLC., which has a financial interest in commercializing imaging technologies for drug discovery and pharmaceutical development.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}